SGSissel Johanne Godtfredsen

Sissel Johanne Godtfredsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sissel Johanne Godtfredsen has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Harman Yonis

    The Department of Cardiovascular Surgery Aalborg University Hospital Aalborg Denmark

    3 shared publications
  • Joachim Baech

    Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark

    3 shared publications
  • Karin E. Smedby

    Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden

    3 shared publications
  • Kristian H. Kragholm

    Department of Cardiology Aalborg University Hospital Aalborg Denmark

    3 shared publications
  • Martin Hutchings

    Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark

    3 shared publications
  • Mikkel Porsborg Andersen

    The Prehospital Center, Region Zealand Naestved Denmark

    3 shared publications

Latest Publications

  • Open Access

    Mortality in Patients With Hodgkin Lymphoma and Heart Failure

    by Sissel Johanne Godtfredsen, Sandra Eloranta, Karin E. Smedby, Stefanie Antonilli, Joachim Baech, Daniel Molin, Kristian Kragholm, Tarec C. El-Galaly, Caroline E. Dietrich

  • Open Access

    Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022

    by Sissel Johanne Godtfredsen, Fanny Bergström, Sara Harrysson, Kristian Kragholm, Tarec C. El-Galaly, Karin E. Smedby, Sandra Eloranta

    Patients with large B-cell lymphoma (LBCL) are at increased risk of heart failure (HF) potentially due to anthracycline-based chemotherapy. However, associations with LBCL treatment intensity, HF subtype, and outcome remain undercharacterized. We conducted a nationwide cohort study of 8453 Swedish patients diagnosed with LBCL (median age 70 years) between 2007 and 2022 and 71 506 matched population comparators without a history of HF. The 5-year cumulative incidence of new-onset HF among patients was 8.1% overall, corresponding to a twofold increased rate, driven mainly by nonischemic HF (hazard ratio [HR]nonischemic, 2.33; 95% confidence interval [CI], 2.16-2.50) and less by ischemic HF (HRischemic, 1.30; 95% CI, 1.04-1.62). An increased rate of new-onset nonischemic HF remained after 2 years of follow-up (HR, 1.78; 95% CI, 1.60-1.94). Few patients had reduced intensity treatment (4 R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone], n = 84) of whom none developed HF. Patients selected for intensive treatment (eg, R-CHOEP with etoposide or dose-adjustment [R-DA-EPOCH]) were not at higher risk of HF compared with those treated with standard R-CHOP (HR, 0.73; 95% CI, 0.58-0.92), although unmeasured differences in baseline fitness or frailty may have influenced treatment selection. After HF onset, patients with LBCL had consistently higher all-cause (but not cardiovascular) mortality than comparators. Our findings indicate that patients with LBCL face a sustained long-term risk of nonischemic HF, highlighting the importance of survivorship care and vigilant HF symptom screening.

  • Open Access

    Long‐Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators

    by Sissel Johanne Godtfredsen, Joachim Baech, Mikkel Porsborg Andersen, Harman Yonis, Paw Jensen, Peter Kamper, Jacob H. Christensen, Rasmus Bo‐Dahl Sørensen, Martin Hutchings, Christian Torp‐Pedersen, et al.

    Survival has improved substantially for patients with Hodgkin lymphoma (HL), but long‐term quality of life (QoL) remains incompletely understood. This was a Danish, nationwide, cross‐sectional study of QoL among persons with a diagnosis of HL matched 1:10 to general population comparators. Questionnaires included the HeartQoL, the European Organization for Research and Treatment of Cancer Quality of Life Core‐30 (QLQ‐C30), the Short Form‐36 (SF‐36), and the EuroQoL Health Questionnaire (EQ‐5D). Mean differences (MD) were estimated using linear regression adjusted for sex and age, and stratified by time since diagnosis (0–5, > 5–10, and > 10 years). Overall, 1777 patients with HL (42% of 4156 invited) and 6166 matched comparators (14% of 41 558 invited) responded, and median age was similar (HL: 59, comparators: 61). Most had classical HL (92%). HL groups had consistently and significantly lower QoL than their respective comparators, with 0–5, > 5–10, and > 10 years post‐diagnosis MDs of −0.27, −0.28, and −0.24 for the HeartQoL, −7.4, −7.6, and −5.6 points for the QLQ‐C30 summary score, −4.5, −4.9, and −4.2 points for the SF‐36 physical component summary, and −0.05, −0.05, and −0.04 for the EQ‐5D index. The relative difference between the HL group and comparators decreased from baseline to > 10 years post‐diagnosis, but differences remained clinically important. The most pronounced symptoms were fatigue and dyspnea. To summarize, persons with HL experience reductions in QoL compared with the general population, even > 10 years post‐diagnosis. The observed differences were clinically relevant within several domains and emphasize the need for a multidisciplinary approach to survivorship care.

  • Open Access

    Congestive heart failure after anthracycline‐containing treatment for Hodgkin lymphoma: A Swedish matched cohort study

    by Joachim Baech, Tarec Christoffer El‐Galaly, Joshua P. Entrop, Ingrid Glimelius, Daniel Molin, Sissel Johanne Godtfredsen, Michael J. Crowther, Karin E. Smedby, Sandra Eloranta, Caroline E. Dietrich

    Introduction: Congestive heart failure (CHF) is a known complication after anthracyclines and radiotherapy for classical Hodgkin lymphoma (cHL). Contemporary cHL treatment may be associated with less risk because radiotherapy use and techniques have changed substantially over time.Methods: In this study, Swedish cHL patients diagnosed in 2000–2018, and treated with adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine (ABVD) or bleomycin, etoposide, Adriamycin [doxorubicin], cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP), were matched 1:10 to the general population on birth year and sex to investigate relative rates and cumulative risks of CHF.Results: A total of 1994 cHL patients were included, with a median age of 34 years. The median follow‐up was 8.1 years. The CHF rate was higher for patients versus comparators (adjusted hazard ratio [HR] = 3.02, 95% confidence interval [CI]: 2.26–4.02). Patients treated with ≤200 mg/m2 of anthracyclines had HR of 2.89 (95% CI: 1.51–3.47) versus 3.91 (95% CI: 2.72–5.60) for >200 mg/m2. Treatment with ABVD was associated with a significantly higher CHF rate (adjusted HR = 3.25, 95% CI: 2.31–4.23), while BEACOPP was not (adjusted HR = 1.95, 95% CI: 0.91–4.16). The increase in relative rates translated to the absolute scale, with an increased risk persisting up to 18 years for low cumulative doses.Conclusion: These findings highlight that cHL survivors still face a substantial excess risk of CHF in the modern treatment era and that focus on cardiovascular health remains relevant.


  • Open Access

    Risk of Cardiovascular Disease in Patients With Classical Hodgkin Lymphoma: A Danish Nationwide Register‐Based Cohort Study

    by Sissel J. Godtfredsen, Harman Yonis, Joachim Baech, Nour R. Al‐Hussainy, Signe Riddersholm, Lars Kober, Morten Schou, Jacob Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl‐Sørensen, et al.

    Risk of cardiovascular disease (CVD) in patients with classical Hodgkin lymphoma (cHL) undergoing contemporary treatment is unclear. cHL patients ≥ 18 years at diagnosis treated with doxorubicin‐containing chemotherapy between 2000 and 2022 were matched 1:5 with comparators on birth year, sex, and Charlson Comorbidity Index at time of matching (score of 0 or ≥ 1). Cause‐specific cumulative incidence of a composite of CVDs with corresponding 95% confidence intervals (CIs) were computed with death and lymphoma relapse as competing events (i.e., by censoring individuals at such occurrences) using the Aalen‐Johansen estimator. A total of 1905 patients and 9525 comparators with a median follow‐up of 10 years (interquartile range, [IQR]: 5.9–17.4). Median age was 39 years (IQR: 27–56), median cumulative doxorubicin dose was 250 mg/m2 (IQR: 200–300). The CVD cumulative incidences were 4.7% (95% CI: 3.6–5.7) for patients versus 2.6% (95% CI: 2.3–2.9) for comparators at 5 years, 8.9% (95% CI: 7.2–10.5) versus 5.5% (95% CI: 4.9–6.0) at 10 years, and 17.0% (95% CI: 14.1–19.9) versus 8.2% (95% CI: 7.4–9.0) at 15 years. CVD remains a substantial effect after contemporary treatment for cHL, suggesting that awareness of symptoms and a low threshold for referral to diagnostic examination are still important measures during survivorship.


  • Open Access

    Risk of cardiovascular disease in patients with classical Hodgkin lymphoma: a Danish nationwide register-based cohort study

    by Sissel J. Godtfredsen, Harman Yonis, Joachim Baech, Nour R. Al-Hussainy, Signe Riddersholm, Lars Kober, Morten Schou, Jacob Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl-Sørensen, et al.

    Aim: To describe the risk of cardiovascular disease (CVD) in patients with classical Hodgkin lymphoma (cHL) undergoing contemporary treatment. Methods: Including all patients with cHL ≥18 years at diagnosis treated with doxorubicin-containing chemotherapy between 2000-2022. Patients were matched with comparators in a 1:5 ratio on birth year, sex, and Charlson Comorbidity Index at time of matching (score of 0 or ≥1). A composite of CVDs including coronary artery disease, heart failure, valvular stenoses, restrictive pericarditis, arrythmias, or any procedures related to these was the primary outcome. Follow-up started on date of cHL diagnosis (i.e., the matching date). The cause-specific cumulative incidence and 95% confidence intervals (CIs) were computed with all-cause death and lymphoma relapse as competing events using the Aalen-Johansen estimator. Results: A total of 1,905 patients with cHL and 9,525 comparators were included. Median age was 39 years (interquartile range, [IQR]: 27-56), 58% were males, most were treated with ABVD (83%), and the median cumulative doxorubicin dose was 250 mg/m 2 (IQR: 200-300). Median follow-up was 10 years (IQR: 5.9-17.4). The cumulative incidences of CVD were 4.7% (95% CI: 3.6-5.7) for patients vs. 2.6% (95% CI: 2.3-2.9) for comparators at 5 years, 8.9% (95% CI: 7.2-10.5) vs. 5.5% (95% CI: 4.9-6.0) at 10 years, and 17.0% (95% CI: 14.1-19.9) vs. 8.2% (95% CI: 7.4-9.0) at 15 years. Conclusions: CVD remains a substantial late effect after contemporary treatment for cHL, suggesting that awareness of cardiac symptoms and a low threshold for referral to diagnostic examination are still important measures during survivorship.

  • Open Access

    Ticagrelor or prasugrel vs. clopidogrel in patients with atrial fibrillation undergoing percutaneous coronary intervention for myocardial infarction

    by Sissel J Godtfredsen, Kristian H Kragholm, Anna Meta Dyrvig Kristensen, Tarek Bekfani, Rikke Sørensen, Maurizio Sessa, Christian Torp-Pedersen, Deepak L Bhatt, Manan Pareek

    The efficacy and safety of ticagrelor or prasugrel vs. clopidogrel in patients with atrial fibrillation (AF) on oral anticoagulation (OAC) undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI) have not been established. This was a nationwide cohort study of patients on OAC for AF who underwent PCI for MI from 2011 through 2019 and were prescribed a P2Y12 inhibitor at discharge. The primary efficacy outcome was major adverse cardiovascular events (MACE), defined as a composite of death from any cause, stroke, recurrent MI, or repeat revascularization. The primary safety outcome was cerebral, gastrointestinal, or urogenital bleeding requiring hospitalization. Absolute and relative risks for outcomes at 1 year were calculated through multivariable logistic regression with average treatment effect modelling. Outcomes were standardized for the individual components of the CHA2DS2-VASc and HAS-BLED scores as well as type of OAC, aspirin, and proton pump inhibitor use. We included 2259 patients of whom 1918 (84.9%) were prescribed clopidogrel and 341 (15.1%) ticagrelor or prasugrel. The standardized risk of MACE was significantly lower in the ticagrelor or prasugrel group compared with the clopidogrel group (standardized absolute risk, 16.3% vs. 19.4%; relative risk, 0.84, 95% confidence interval, 0.70–0.98; P = 0.02), while the risk of bleeding did not differ (standardized absolute risk, 5.5% vs. 5.1%; relative risk, 1.07, 95% confidence interval, 0.73–1.41; P = 0.69). In patients with AF on OAC who underwent PCI for MI, treatment with ticagrelor or prasugrel vs. clopidogrel was associated with reduced ischaemic risk, without a concomitantly increased bleeding risk.


  • Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study

    by Sissel J Godtfredsen, Kristian H Kragholm, Peter Leutscher, Steen Hylgaard Jørgensen, Martin Kirk Christensen, Jawad H Butt, Gunnar Gislason, Lars Køber, Emil L Fosbøl, Maurizio Sessa, et al.

    To compare the effectiveness and safety of clopidogrel, ticagrelor, and prasugrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Nationwide, registry-based study of STEMI patients treated with primary PCI (2011–17) and subsequently with aspirin and a P2Y12 inhibitor. The effectiveness outcome was major adverse cardiovascular events (MACE) defined as a composite of recurrent myocardial infarction, repeat revascularization, stroke, or cardiovascular death at 12 months. The safety outcome was bleeding requiring hospitalization at 12 months. Multivariable logistic regression with average treatment effect modeling was used to calculate absolute and relative risks for outcomes standardized to the distributions of demographic characteristics of all included subjects. We included 10 832 patients; 1 697 were treated with clopidogrel, 7 508 with ticagrelor, and 1,627 with prasugrel. Median ages were 66, 63, and 59 years (P < 0.001). Standardized relative risks of MACE were 0.75 for ticagrelor vs. clopidogrel (95% confidence interval [CI], 0.64–0.83), 0.84 for prasugrel vs. clopidogrel (95% CI, 0.73–0.94), and 1.12 for prasugrel vs. ticagrelor (95% CI, 1.00–1.24). Standardized relative risks of bleeding were 0.77 for ticagrelor vs. clopidogrel (95% CI, 0.59–0.93), 0.89 for prasugrel vs. clopidogrel (95% CI, 0.64–1.15), and 1.17 for prasugrel vs. ticagrelor (95% CI, 0.89–1.45). Ticagrelor and prasugrel were associated with lower risks of MACE after STEMI than clopidogrel, and ticagrelor was associated with a marginal reduction compared with prasugrel. The risk of bleeding was lower with ticagrelor compared with clopidogrel, but did not significantly differ between ticagrelor and prasugrel. Summary of major findings in ‘effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide register-based study’. Abbreviations: C, clopidogrel; T, ticagrelor; P, prasugrel; MACEs, major adverse cardiovascular events.